secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001193125-26-120864
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering
--------------------------------------------------------------------------------

- Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.
- Phase 2a cardiovascular trial planned 1H 2026; ophthalmology expansion with DME trial mid-2026.
- Completed $132.3M follow-on offering in Feb 2026; cash $285.1M at Dec 31, 2025, sufficient through 2029.
- FY2025: collaboration revenue $9.0M (vs $0); net loss $80.6M ($2.24/share) vs $71.1M ($6.63/share) in 2024.
- APJ agonist programs advancing; IND filing expected by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/0001193125-26-120864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/bioa-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-120864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer